Subject Index
Coagulation Factors and Inhibitors
Fibrinolysis, fibrinogen, fibrin
Haemorrhagic Disorders
Invited
Other
Platelets
Thrombotic Disorders and antithrombotic therapy
Vascular Biology
Coagulation Factors and Inhibitors
Animal and experimental models
AT, HCII, serine protease inhibitors
Contact phase
Factor IX and vitamin K-dependent factors
Factor XIII
Factor VIII, factor V
Methods
Other coagulation factors and inhibitions
Procoagulant phospholipids
Protein C, protein S, thrombomodulin
Structural biology and drug design
Thrombin, thrombin receptors
Tissue factor, TFPI, factor VII
A novel r-polypeptide, kunitz-type inhibitor with high specificity for plasma kallikrein and potential for therapeutic use
Mackie I., Purdy G., Lawrie A. S., Williams A., Machin S. J.
Contact system activation, FXIIa and plasma kallikrein produce enhanced fibrinolysis in urokinase induced fibrinolysis in thromboelastography: (UKIFTEG)
Gallimore M., Jones D. W., Tappenden K., Winter M.
Cost-effectiveness in establishing carrier detection and prenatal diagnosis services in a developing country with limited health resources
Sasankul W., Chuansumrit A., Ajjimakorn S., Krasaesub S., Sirachainan N., Chotsupakarn S., Kadegasem P., Rurgkhum S.
Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells
Baird T. R., Walsh P. N.
Proteoglycans dock kininogens to cells and regulate generate bradykinin generation
Renné T., Müller-Esterl W., Walter U.
Recombinant prolylcarboxypeptidase activates plasma prekallikrein
Shariat-Madar Z., Mahdi F., Schmaier A. H.
Surface deposited fibrin activates factor XII and the intrinsic coagulation pathway
Sanchez J., Larsson R., Olsson P.
Whole blood thromboelastography and platelet function studies with DX-88, a Kunitz-type inhibitor of kallikrein
Wilbourn B. R., Mackie I. J., Jenkins A. H., Williams A., Machin S. J.